SMO ClinPlus CO.,LTD.

SZSE:301257 Rapporto sulle azioni

Cap. di mercato: CN¥2.3b

SMO ClinPlusLTD Performance dei guadagni passati

Il passato criteri di controllo 1/6

SMO ClinPlusLTD has been growing earnings at an average annual rate of 28.3%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 21.2% per year. SMO ClinPlusLTD's return on equity is 9.3%, and it has net margins of 13.1%.

Informazioni chiave

28.3%

Tasso di crescita degli utili

21.2%

Tasso di crescita dell'EPS

Life Sciences Crescita del settore26.8%
Tasso di crescita dei ricavi21.2%
Rendimento del capitale proprio9.3%
Margine netto13.1%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

SMO ClinPlusLTD's (SZSE:301257) Promising Earnings May Rest On Soft Foundations

May 05
SMO ClinPlusLTD's (SZSE:301257) Promising Earnings May Rest On Soft Foundations

Recent updates

SMO ClinPlus CO.,LTD. (SZSE:301257) Held Back By Insufficient Growth Even After Shares Climb 32%

Sep 30
SMO ClinPlus CO.,LTD. (SZSE:301257) Held Back By Insufficient Growth Even After Shares Climb 32%

Little Excitement Around SMO ClinPlus CO.,LTD.'s (SZSE:301257) Earnings As Shares Take 37% Pounding

Jun 06
Little Excitement Around SMO ClinPlus CO.,LTD.'s (SZSE:301257) Earnings As Shares Take 37% Pounding

SMO ClinPlusLTD's (SZSE:301257) Promising Earnings May Rest On Soft Foundations

May 05
SMO ClinPlusLTD's (SZSE:301257) Promising Earnings May Rest On Soft Foundations

Ripartizione dei ricavi e delle spese

Come SMO ClinPlusLTD guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

SZSE:301257 Ricavi, spese e utili (CNY Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 248101066535
30 Jun 248061286535
31 Mar 247871326337
31 Dec 237601356135
30 Sep 237291355434
30 Jun 236901155434
31 Mar 23621885232
01 Jan 23586725632
30 Sep 22542525229
30 Jun 22523504926
31 Mar 22528585329
31 Dec 21503584021
30 Sep 21472586730
30 Jun 21421533817
31 Mar 21373464415
31 Dec 20335354415
31 Dec 19304522416
31 Dec 18193301712
30 Sep 18172291211
30 Jun 1814726165
31 Mar 1813223163
31 Dec 1711620115
30 Sep 179814103
30 Jun 17809101
31 Mar 1772890
31 Dec 1663880
31 Dec 1542-14240

Guadagni di qualità: 301257 has a high level of non-cash earnings.

Margine di profitto in crescita: 301257's current net profit margins (13.1%) are lower than last year (18.5%).


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: 301257's earnings have grown significantly by 28.3% per year over the past 5 years.

Accelerare la crescita: 301257's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Guadagni vs Settore: 301257 had negative earnings growth (-21.5%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).


Rendimento del capitale proprio

ROE elevato: 301257's Return on Equity (9.3%) is considered low.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate